TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model

. 2022 Sep 6;25(10):105074. doi: 10.1016/j.isci.2022.105074

Group	N	Treatment (SQ)	Dose	Tx Days	Challenge (IN)	Weights and Clinical Observations^a	Blood Collection (SST)^b	Oral Swabs	Tissue Collection^c
1	8 (4F/4M)	Vehicle Control	1.5 mL	2 HR pre-Challenge BID on SD 1-3 SID on SD 4-9	SD 0: SARS-CoV-2	Daily weights and BID observations during challenge period COVID scoring during AM observations	Pre-Treatment Pre-Challenge on SD 0, Max Bleed at Termination	SD 2, 4, 7, 10 (TCID₅₀)	2/grp/sex on SD 4, 10: Collect lungs and nasal turbinates
2	8 (4F/4M)	TEMPOL	50 or 25 mg/kg in 1.5 mL	2 HR pre-Challenge BID on SD 1-3 SID on SD 4-9	SD 0: SARS-CoV-2			SD 2, 4, 7, 10 (TCID₅₀)	2/grp/sex on SD 4, 10: Collect lungs and nasal turbinates

IN; intranasal.

^aObserve animals once on each day blood is collected or animals are anesthetized. Observe twice daily during challenge period.

^bBlood processing and assay instructions.

^cLeft lungs were preserved in 10% NBF for histopathology. Right lungs and nasal turbinates 1 section (0.05-0.1g) were snap frozen for PCR and 1 section (0.1-0.2g) snap frozen for TCID₅₀.